BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing. Individual investors, including senior management of the company, provided a $2 million equity round. Aduro has also secured an additional $2.7 million in funding through grants and contracts from the Department of Defense for development of a therapeutic vaccine for Hepatitis C, and from the National Institute of Allergy and Infectious Diseases (via the University of New Mexico) for the development of a prophylactic vaccine against the bio-terror agent that causes tularemia.
